Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and ...

Shares of Hello Group Inc. MOMO -9.16% Get Free Report fell sharply during pre-market trading after reporting weak quarterly results. Hello Group posted fourth-quarter adjusted EPADS of 18 cents ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.

In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...

Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...

HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $30.00 price ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN ...

European shares were lower today. The eurozone's STOXX 600 fell 1.28%, Germany's DAX 40 fell 1.86% and France's CAC 40 fell 0 ...

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...